Germline Mutational Profile of Triple-Negative Breast Cancer in Portugal: A Multicenter Retrospective Cohort Study

Background/Objectives: Triple-negative breast cancer (TNBC) carries a poor prognosis; while PARP inhibitors (PARPi) are approved for BRCA-mutated disease, other homologous recombination deficiency (HRD) pathways may be actionable targets. This study characterizes germline mutations in Portuguese TNBC and explores exploratory associations with clinicopathologic features and outcomes. Methods: A multicentric retrospective cohort of women diagnosed with TNBC (2022–2024) that harbored a pathogenic variant (PV), likely pathogenic variant (LPV), or variant of uncertain significance (VUS) across six Portuguese institutions. Clinicopathologic variables were compared between groups. Overall (OS) and progression-free survival (PFS) were estimated in patients eligible for curative-intent therapy with PV/LPV, using Kaplan–Meier and log-rank methods. Results: Among 109 patients, 38.5% carried a PV and 11.0% an LPV. BRCA1/2 predominated among PV carriers (59.5%), followed by PALB2 (9.5%), RAD51C (7.1%), and RAD51D (4.8%). Additionally, 53.2% harbored a VUS, mainly ATM (22.4%), CHEK2/BRCA2 (8.6% each), and NF1 (6.9%). Mean age was 49.7 ± 12.1 years; 49.5% had advanced-stage disease (>cT2/N+); 61.5% received neoadjuvant immunotherapy; 1.8% received adjuvant PARPi. For efficacy analysis, BRCA (n = 26) and non-BRCA (n = 25) carriers were well balanced. Pathologic complete response occurred in 60.9% of non-BRCA versus 82.6% of BRCA carriers (p = 0.190). BRCA carriers had numerically higher PFS (p = 0.09): 92.3% versus 69.7% at 24 months. OS was comparable (p = 0.16); median OS not reached. Conclusions: This study characterizes the germline landscape of Portuguese TNBC, revealing diverse HRD-pathway mutations beyond BRCA. In this small exploratory analysis, BRCA status was not associated with a statistically significant difference in PFS, pathologic response, or OS.

Authors

Institutions

Publication Details

Journal
DNA
Published
2026-11-12
DOI
https://doi.org/10.3390/dna6040057
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Germline Mutational Profile of Triple-Negative Breast Cancer in Portugal: A Multicenter Retrospective Cohort Study

Olga L. Caramelo, Sofia Broco, Ricardo Roque, Tatiana Cunha Pereira et al.
DNA
BRCA gene mutations in cancer
article

Germline Mutational Profile of Triple-Negative Breast Cancer in Portugal: A Multicenter Retrospective Cohort Study

Olga L. Caramelo, Sofia Broco, Ricardo Roque, Tatiana Cunha Pereira, Teresa Fraga, Teresa Carvalho, Susana Almeida, Isalia Margarida Campos Miguel, Gabriela Araujo Sousa, Marta Serafim Gonçalves, Inês Baptista Freitas, Patrícia Gago
article en

Abstract

Background/Objectives: Triple-negative breast cancer (TNBC) carries a poor prognosis; while PARP inhibitors (PARPi) are approved for BRCA-mutated disease, other homologous recombination deficiency (HRD) pathways may be actionable targets. This study characterizes germline mutations in Portuguese TNBC and explores exploratory associations with clinicopathologic features and outcomes. Methods: A multicentric retrospective cohort of women diagnosed with TNBC (2022–2024) that harbored a pathogenic variant (PV), likely pathogenic variant (LPV), or variant of uncertain significance (VUS) across six Portuguese institutions. Clinicopathologic variables were compared between groups. Overall (OS) and progression-free survival (PFS) were estimated in patients eligible for curative-intent therapy with PV/LPV, using Kaplan–Meier and log-rank methods. Results: Among 109 patients, 38.5% carried a PV and 11.0% an LPV. BRCA1/2 predominated among PV carriers (59.5%), followed by PALB2 (9.5%), RAD51C (7.1%), and RAD51D (4.8%). Additionally, 53.2% harbored a VUS, mainly ATM (22.4%), CHEK2/BRCA2 (8.6% each), and NF1 (6.9%). Mean age was 49.7 ± 12.1 years; 49.5% had advanced-stage disease (>cT2/N+); 61.5% received neoadjuvant immunotherapy; 1.8% received adjuvant PARPi. For efficacy analysis, BRCA (n = 26) and non-BRCA (n = 25) carriers were well balanced. Pathologic complete response occurred in 60.9% of non-BRCA versus 82.6% of BRCA carriers (p = 0.190). BRCA carriers had numerically higher PFS (p = 0.09): 92.3% versus 69.7% at 24 months. OS was comparable (p = 0.16); median OS not reached. Conclusions: This study characterizes the germline landscape of Portuguese TNBC, revealing diverse HRD-pathway mutations beyond BRCA. In this small exploratory analysis, BRCA status was not associated with a statistically significant difference in PFS, pathologic response, or OS.

DNAVol. 6(4)
Instituto Português de Oncologia de Coimbra Francisco Gentil (PT), Hospitais da Universidade de Coimbra (PT), Instituto Português de Oncologia Francisco Gentil (PT), IPO Porto (PT), Association for the Development of Douro Viticulture (PT), Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
Good health and well-being
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon